redefining cell culture in life science

---

WE ARE denovoMATRIX
We mimic the cell microenvironment that determines cell fate and function.

---

Advisors

redefining cell culture in life science

---

TERMIS BUSINESS PLAN COMPETITION 2017
[30.06.2017]

UPDATE: ON THE PODIUM!
We are proud to announce that our business concept convinced the jury in Davos, and we won the 3rd prize. Thanks to all our supporters!

UPDATE: FINAL ROUND!
We made it to the final round of the TERMIS business plan competition! Check out our video pitch below that was part of our application package to convince the jury! Thanks to all for your support, and please keep your fingers crossed: Now, we are one out of five final teams that will pitch at the TERMIS-EU 2017 Conference on 27th June in Davos, Switzerland!

---

BIOTECHNICA | LABVOLUTION 2017
[12.05.2017]

We will be at the Biotechnica | Labvolution this year from 16^th to 18^th of May. Meet us at the "Gemeinschaftsstand Forschung für die Zukunft" in hall 20, booth C66. Looking forward to meeting you in Hanover!

---

A BUSINESS COACH FOR DENOVOMATRIX
[07.03.2017]

We are glad to announce that Dr. Dragan Grabulovski has joined us as our business coach and will help us with identifying our best business opportunities and to reach our strategic objectives!

Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen's CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. He was a main inventor of the Fynomer technology, established a portfolio of novel bispecific FynomAb product candidates and managed the internal and collaboration pipeline. As a member of Covagen's executive management team, Dr. Grabulovski was instrumental in Covagen's trade sale to Johnson & Johnson, and in the closing of Covagen's CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master's degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH). He is a co-author of several peer-reviewed articles, reviews, book chapters, poster abstracts, patent applications and granted patents.

"I am impressed by the technology developed at Technische Universität Dresden that improves the cell microenvironment of standard cell culture assays, enabling researchers to perform cell assays that were challenging or impossible in the past and yielding better and reproducible results in general," said Dr. Dragan Grabulovski.

We had supportive and intense discussion during a fruitful meeting in Dresden last week, and we are very much looking forward to our future collaboration!

---

QUICKSTART
[21.10.2016]

denovoMATRIX awarded with bionection Technology Transfer Trophy for successful commercialization development

Just recently started at B-CUBE, the validation team denovoMATRIX already received their first award on Tuesday: the bionection Technology Transfer Trophy for best commercialization development over the last 12 month. The trophy was awarded during the bionection technology transfer conference by biosaxony, the biotech and medtech cluster agency of Saxony, and is endowed with 1,500 EUR and a consulting package of KPMG. Based on a patented technology that was developed in the B-CUBE lab of Yixin Zhang, denovoMATRIX develops novel in vivo-mimicking biomaterials for optimal cell culture conditions.